logo-loader
viewArecor

Arecor pushes to meet unmet needs in diabetes care

Snapshot

Arecor is waiting for the results from phase I clinical trials of its ultra-rapid acting insulin candidate, AT247, expected by the end of the year

Arecor -

What Arecor does

Arecor Limited is a privately-owned biopharmaceuticals company developing superior diabetes care through the application of its innovative formulation technology platform.

Arecor is leveraging this platform to: 

(i) develop a portfolio of proprietary products for diabetes care

(ii) deliver superior reformulations of its partners proprietary products.

It partners with major pharma and biotech companies to develop improved versions of their key products, as well as developing its own products.

Inflexion points

In October, Arecor Limited signed a research, development and commercialisation agreement with JDRF, the world's leading type 1 diabetes research charity.

Under the collaboration, Arecor and JDRF will invest equal funds to develop AT271, a liquid combination of insulin and pramlintide, which is used to replace a hormone absent in people with type 1 diabetes.

The company said it had demonstrated the combined injection of these two drugs at mealtimes helps with controlling the blood sugar level, losing weight and reducing insulin doses.

It noted that pramlintide is currently “underutilised” because there is no combined injectable solution containing insulin and patients need to carry out separate injections.

Arecor will use its proprietary formulation technology platform, Arestat to develop a new, co-formulation of pramlintide and insulin.

Elsewhere, the company also finished dosing and patient visits in the Austria-based phase I of its ultra-rapid acting insulin candidate, AT247, with results expected by the end of the year.

The product is designed to improve treatment for people living with Type I diabetes, by accelerating insulin absorption to manage more effectively blood glucose levels, especially after meals.

Watch the interview

What the boss says

Chief executive Dr Sarah Howell said that diabetes has hit “epidemic proportions” with 425mln sufferers worldwide.

Howell noted: “There’s still an unmet need for these faster-acting insulins that are really more like a physicological insulin, so match a healthy person’s response to spikes in blood glucose.”

“Really now the focus is on progressing all of our assets and all of our products into clinical stages and proving the clinical benefits and healthcare outcomes," she added.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arecor named herein, including the promotion by the Company of Arecor in any Content on the Site, the Company receives from said issuer annual...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Arecor completes dosing in its Phase I clinical trial and...

Arecor's Sarah Howell tells Proactive London's Andrew Scott they've now completed dosing and patient visits in the Austria-based phase I study of its ultra-rapid acting insulin candidate, AT247, with results expected by the end of the year. They've also signed a research, development and...

1 week, 3 days ago

2 min read